CoChat

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Lurasidone as Adjunctive Therapy With Lithium or Valproate for the Treatment of Bipolar I Depression: A Randomized, Double-Blind, Placebo-Controlled Study

Loebel, Antony, Cucchiaro, Josephine, Silva, Robert, Kroger, Hans, Sarma, Kaushik, Xu, Jane, Calabrese, Joseph R. · 2014 · American Journal of Psychiatry

Abstract

OBJECTIVE Few studies have been reported that support the efficacy of adjunctive therapy for patients with bipolar I depression who have had an insufficient response to monotherapy with mood-stabilizing agents. The authors investigated the efficacy of lurasidone, a novel antipsychotic agent, as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression. METHOD Patients were randomly assigned to receive 6 weeks of double-blind adjunctive treatment with lurasidone (N=183) or placebo (N=165), added to therapeutic levels of either lithium or valproate. Primary and key secondary endpoints were change from baseline to week 6 on the Montgomery-Åsberg Depression Rating Scale (MADRS) and depression severity score on the Clinical Global Impressions scale for use in bipolar illness (CGI-BP), respectively. RESULTS Lurasidone treatment significantly reduced mean MADRS total score at week 6 compared with the placebo group (-17.1 versus -13.5; effect size=0.34). Similarly, lurasidone treatment resulted in significantly greater endpoint reduction in CGI-BP depression severity scores compared with placebo (-1.96 versus -1.51; effect size=0.36) as well as significantly greater improvement in anxiety symptoms and in patient-reported measures of quality of life and functional impairment. Discontinuation rates due to adverse events were 6.0% and 7.9% in the lurasidone and placebo groups, respectively. Adverse events most frequently reported for lurasidone were nausea, somnolence, tremor, akathisia, and insomnia. Minimal changes in weight, lipids, and measures of glycemic control were observed during treatment with lurasidone. CONCLUSIONS In patients with bipolar I depression, treatment with lurasidone adjunctive to lithium or valproate significantly improved depressive symptoms and was generally well tolerated.

Overview

Integrity signals

Registry

Crossref · 10.1176/appi.ajp.2013.13070985

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 40 references

Research works printed but not linked: 3

  1. Sheehan DV, 1998, J Clin Psychiatry, 59, 22
  2. Endicott J, 1993, Psychopharmacol Bull, 29, 321
  3. Loebel A, Am J Psychiatry

Cited by

See all 293

Metadata

Authors
Loebel, A., Cucchiaro, J., Silva, R., Kroger, H., Sarma, K., Xu, J., & Calabrese, J. R.
Affiliations
University Hospitals Cleveland Medical Center (US)
Venue
American Journal of Psychiatry
Published
2014-02
Volume
171
Issue
2
Pages
169-177
ISSN
  • 0002-953X (ISSN-L)
  • 1535-7228
OpenAlex
W2107950329
Cited by
293
References
40
Citations by year
2026: 4 · 2025: 12 · 2024: 14 · 2023: 16 · 2022: 16 · 2021: 23 · 2020: 24 · 2019: 50 · 2018: 11 · 2017: 20 · 2016: 17 · 2015: 53 · 2014: 27
FWCI
23.83
Type
journal article
Language
en
Open access
closed
Locations
  • American Journal of Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
lurasidone, bipolar I depression, adjunctive therapy, lithium, valproic acid, atypical antipsychotics, mood stabilizers, treatment-resistant depression, depression severity, adverse events, quality of life, functional disability
MeSH terms
Lurasidone Hydrochloride, Adolescent, Adult, Aged, Bipolar Disorder, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Thiazoles, Antipsychotic Agents, Valproic Acid, Lithium Compounds, Antimanic Agents, Isoindoles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lurasidone as Adjunctive Therapy With Lithium or Valproate for the Treatment of Bipolar I Depression: A Randomized, Double-Blind, Placebo-Controlled Study. https://app.cochat.ai/papers/10.1176/appi.ajp.2013.13070985
The paper
Loebel, A., Cucchiaro, J., Silva, R., Kroger, H., Sarma, K., Xu, J., & Calabrese, J. R. (2014). Lurasidone as Adjunctive Therapy With Lithium or Valproate for the Treatment of Bipolar I Depression: A Randomized, Double-Blind, Placebo-Controlled Study. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.2013.13070985

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.